|
1
|
Salmon WD Jr and Daughaday WH: A
hormonally controlled serum factor which stimulates sulfate
incorporation by cartilage in vitro. J Lab Clin Med. 49:825–836.
1957.
|
|
2
|
Maki RG: Small is beautiful: insulin-like
growth factors and their role in growth, development, and cancer. J
Clin Oncol. 28:4985–4995. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sell C, Rubini M, Rubin R, et al: Simian
virus 40 large tumor antigen is unable to transform mouse embryonic
fibroblasts lacking type 1 insulin-like growth factor receptor.
Proc Natl Acad Sci USA. 90:11217–11221. 1993. View Article : Google Scholar
|
|
4
|
Werner H: Tumor suppressors govern
insulin-like growth factor signaling pathways: implications in
metabolism and cancer. Oncogene. 31:2703–2714. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seccareccia E and Brodt P: The role of the
insulin-like growth factor-I receptor in malignancy: an update.
Growth Horm IGF Res. 22:193–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fire A, Xu S, Montgomery MK, et al: Potent
and specific genetic interference by double-stranded RNA in
Caenorhabditis elegans. Nature. 391:806–811. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Deng Y, Wang CC, Choi KW, et al:
Therapeutic potentials of gene silencing by RNA interference:
principles, challenges, and new strategies. Gene. 538:217–227.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Castel SE and Martienssen RA: RNA
interference in the nucleus: roles for small RNAs in transcription,
epigenetics and beyond. Nat Rev Genet. 14:100–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guo J, Evans JC and O’Driscoll CM:
Delivering RNAi therapeutics with non-viral technology: a promising
strategy for prostate cancer? Trends Mol Med. 19:250–261. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Levine AJ and Oren M: The first 30 years
of p53: growing ever more complex. Nat Rev Cancer. 9:749–758.
2009.PubMed/NCBI
|
|
11
|
Lane DP, Cheok CF and Lain S: p53-based
cancer therapy. Cold Spring Harb Perspect Biol.
2:a0012222010.PubMed/NCBI
|
|
12
|
Oren M and Rotter V: Mutant p53
gain-of-function in cancer. Cold Spring Harb Perspect Biol.
2:a0011072010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ge J, Chen Z, Wu S, et al: Expression
levels of insulin-like growth factor-1 and multidrug
resistance-associated protein-1 indicate poor prognosis in patients
with gastric cancer. Digestion. 80:148–158. 2009. View Article : Google Scholar
|
|
14
|
Werner H, Karnieli E, Rauscher FJ and
LeRoith D: Wild-type and mutant p53 differentially regulate
transcription of the insulin-like growth factor I receptor gene.
Proc Natl Acad Sci USA. 93:8318–8323. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nahor I, Abramovitch S, Engeland K and
Werner H: The p53-family members p63 and p73 inhibit insulin-like
growth factor-I receptor gene expression in colon cancer cells.
Growth Horm IGF Res. 15:388–396. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maor S, Yosepovich A, Papa MZ, et al:
Elevated insulin-like growth factor-I receptor (IGF-IR) levels in
primary breast tumors associated with BRCA1 mutations. Cancer Lett.
257:236–243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maor SB, Abramovitch S, Erdos MR, Brody LC
and Werner H: BRCA1 suppresses insulin-like growth factor-I
receptor promoter activity: potential interaction between BRCA1 and
Sp1. Mol Genet Metab. 69:130–136. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yuen JS, Cockman ME, Sullivan M, et al:
The VHL tumor suppressor inhibits expression of the IGF1R and its
loss induces IGF1R upregulation in human clear cell renal
carcinoma. Oncogene. 26:6499–6508. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Werner H, Re GG, Drummond IA, et al:
Increased expression of the insulin-like growth factor I receptor
gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R
promoter activity by the WT1 Wilms tumor gene product. Proc Natl
Acad Sci USA. 90:5828–5832. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Werner H, Shen-Orr Z, Rauscher FJ III, et
al: Inhibition of cellular proliferation by the Wilms’ tumor
suppressor WT1 is associated with suppression of insulin-like
growth factor I receptor gene expression. Mol Cell Biol.
15:3516–3522. 1995.
|
|
21
|
Niu J, Xu Z, Li XN and Han Z:
siRNA-mediated type 1 insulin-like growth factor receptor silencing
induces chemosensitization of a human liver cancer cell line with
mutant P53. Cell Biol Int. 31:156–164. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Min Y, Adachi Y, Yamamoto H, et al:
Insulin-like growth factor I receptor blockade enhances
chemotherapy and radiation responses and inhibits tumour growth in
human gastric cancer xenografts. Gut. 54:591–600. 2005. View Article : Google Scholar
|
|
23
|
Tian D and Kreeger PK: Analysis of the
quantitative balance between insulin-like growth factor (IGF)-1
ligand, receptor, and binding protein levels to predict cell
sensitivity and therapeutic efficacy. BMC Syst Biol. 8:982014.
View Article : Google Scholar
|
|
24
|
Denley A, Cosgrove LJ, Booker GW, Wallace
JC and Forbes BE: Molecular interactions of the IGF system.
Cytokine Growth Factor Rev. 16:421–439. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pollak MN, Schernhammer ES and Hankinson
SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer.
4:505–518. 2004. View
Article : Google Scholar : PubMed/NCBI
|
